Sem@x

Sem@x exerts its effects through multiple mechanisms of action. It has been shown to modulate the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are crucial for neuronal survival, growth, and plasticity. Sem@x also enhances the activity of the serotonergic and dopaminergic systems, neurotransmitters involved in mood regulation, motivation, and cognitive functions. Additionally, Sem@x exhibits antioxidant and anti-inflammatory properties, protecting neurons from oxidative stress and inflammation-induced damage. It has been found to reduce the accumulation of beta-amyloid peptides, which are implicated in the pathogenesis of Alzheimer's disease. Sem@x also improves blood circulation in the brain, enhancing oxygen and nutrient delivery to neural tissues.

Research studies have highlighted several potential benefits of Sem@x peptide

1. Cognitive enhancement Sem@x has been shown to improve memory, learning, and attention in various animal models and clinical trials. It may enhance cognitive performance in healthy individuals and those with cognitive impairments.

2. Neuroprotection Sem@x exhibits neuroprotective properties, reducing neuronal damage and promoting neuronal survival in the face of various insults, such as ischemia, trauma, and neurodegenerative diseases.

3. Mood regulation Sem@x has been investigated for its potential anxiolytic and antidepressant effects, possibly through its modulation of serotonergic and dopaminergic systems.

4. Stroke recovery Sem@x has shown promise in promoting functional recovery and reducing neurological deficits following ischemic stroke in animal models.

5. Neurodegenerative disorders Sem@x has been explored as a potential therapeutic agent for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, due to its neuroprotective and cognitive-enhancing properties.

• Sem@x is generally well-tolerated, with few reported side effects in clinical trials. However, as with any research compound, caution should be exercised, and further studies are needed to fully understand its safety profile. Potential side effects may include

• Headache

• Dizziness

• Allergic reactions in sensitive individuals.

Sem@x peptide is a promising research compound with potential cognitive-enhancing, neuroprotective, and mood-regulating properties. Its ability to modulate neurotrophic factors, neurotransmitter systems, and inflammatory processes has sparked interest in its therapeutic potential for various neurological disorders. While the results from preclinical studies and clinical trials are encouraging, further research is needed to fully elucidate its mechanisms of action, safety profile, and clinical applications. As a research chemical, Sem@x peptide offers a valuable tool for investigating the complexities of the brain and developing novel therapies for neurological conditions.

1. Glazova NY, Manchenko DM, Volodina MA, Merchieva SA, Andreeva LA, Kudrin VS, Myasoedov NF, Levitskaya NG. Sem@x, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2021 Apr;86:102114. doi: 10.1016/j.npep.2020.102114. Epub 2020 Dec 28. PMID: 33418449.

2. Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. Sem@x, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. ACS Chem Neurosci. 2022 Feb 16;13(4):486-496. doi: 10.1021/acschemneuro.1c00707. Epub 2022 Jan 26. PMID: 35080861; PMCID: PMC8855339.

3. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Grivennikov IA, Myasoedov NF. Sem@x, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006.

4. Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV. Sem@x, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. 2017 Jun;292(3):635-653. doi: 10.1007/s00438-017-1297-1. Epub 2017 Mar 2. PMID: 28255762.

5. Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. Éffektivnost' semaksa pri lechenii bol'nykh na raznykh stadiiakh ishemicheskogo insul'ta [The efficacy of Sem@x in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. Russian. doi: 10.17116/jnevro20181183261-68. PMID: 29798983.

6. Lebedeva IS, Panikratova YR, Sokolov OY, Kupriyanov DA, Rumshiskaya AD, Kost NV, Myasoedov NF. Effects of Sem@x on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018 Sep;165(5):653-656. doi: 10.1007/s10517-018-4234-3. Epub 2018 Sep 17. PMID: 30225715.

7. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Sem@x and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010 Jan;30(1):71-9. doi: 10.1007/s10571-009-9432-0. Epub 2009 Jul 25. PMID: 19633950.

8. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide Sem@x affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014 Mar 24;15:228. doi: 10.1186/1471-2164-15-228. PMID: 24661604; PMCID: PMC3987924.

9. Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF. Functional Connectomic Approach to Studying Selank and Sem@x Effects. Dokl Biol Sci. 2020 Jan;490(1):9-11. doi: 10.1134/S001249662001007X. Epub 2020 Apr 27. PMID: 32342318.

10. Inozemtsev AN, Bokieva SB, Karpukhina OV, Gumargalieva KZ, Kamensky AA, Myasoedov NF. Sem@x prevents learning and memory inhibition by heavy metals. Dokl Biol Sci. 2016 May;468(1):112-4. doi: 10.1134/S0012496616030066. Epub 2016 Jul 14. PMID: 27411820.